Hla Drb1 — Mhc Class Ii Dr Beta 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HLA-DRB1 encodes the beta chain of the HLA-DR heterodimer, a major histocompatibility complex (MHC) class II molecule expressed on antigen-presenting cells. HLA-DRB1 plays a central role in the adaptive immune system by presenting peptide antigens to CD4+ T cells. GWAS have identified HLA-DRB1 as a significant genetic risk factor for late-onset Alzheimer's disease (LOAD), linking immune system genetics to neurodegeneration.[1]
HLA-DRB1 is a 266 amino acid beta chain that pairs with the alpha chain (HLA-DRA) to form the functional HLA-DR heterodimer. This complex is expressed on the surface of professional antigen-presenting cells including dendritic cells, macrophages, and B cells.[2]
Key normal functions include:
HLA-DRB1 has been consistently associated with LOAD risk through GWAS, with the HLA-DRB1*15:01 allele showing the strongest association. This suggests that immune genetic factors play a significant role in AD pathogenesis.[1][3]
Mechanisms in AD:
HLA-DRB1*15:01 is one of the strongest genetic risk factors for multiple sclerosis (MS), an autoimmune demyelinating disease.
HLA-DRB1 alleles containing the "shared epitope" (SE) motif are major risk factors for rheumatoid arthritis.
HLA-DRB1 shows cell-type specific expression:
HLA-DRB1-based therapeutic strategies:
The study of Hla Drb1 — Mhc Class Ii Dr Beta 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] HLA-DRB1 and Alzheimer disease risk. PMID:24162737
References
[1] Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-1458.
[2] Janeway CA, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. Garland Science; 2001.
[3] Craig D, et al. HLA-DRB1*15:01 status and age at onset of Alzheimer's disease. JAMA Neurol. 2013;70(10):1321-1322.
[4] Wood WE, et al. MHC class II expression in the brain: implications for Alzheimer's disease. Brain Pathol. 2014;24(4):345-356.